Refine by
Patient Ambulation Articles & Analysis
15 news found
“Robust research is imperative to truly usher in a new class of treatments for these patients in dire need and historically Duchenne trials have not focused of the most severely affected non-ambulatory patients with the greatest disease burden,” said Dr. ...
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. ...
SANTA CLARA, Calif., July 16, 2020 -- Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the first patient enrollments in its AMBULATE Same Day Discharge study, the first prospective multi-center study designed to evaluate same-day discharge for patients undergoing cardiac ablation procedures for atrial ...
The symposium will feature recent clinical experience from several leading U.S. structural heart centers, highlighting the safety and efficacy of the Tempo Lead, its use in TAVR procedures, and its positive impact on facilitating post-TAVR patient ambulation outside of the ICU and CCU. The session will also provide an opportunity for hands-on demonstrations. ...
The symposium will feature recent clinical experience and case studies from several leading U.S. structural heart centers, highlighting the safety and efficacy of the Tempo Lead, its use in TAVR procedures, its positive impact on facilitating post-TAVR patient ambulation outside of the ICU and CCU, and its role in reducing length of stay. ...
Battery back-up was added to make patient ambulation and transfer seemless and without any interruption in patient data. ...
In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as TAVR and TMVR, accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU. ...
THE AMBULATE PIVOTAL STUDY The AMBULATE study was a randomized, controlled clinical trial that enrolled 204 patients who underwent arrhythmia ablation procedures by 28 physicians at 13 sites across the United States. ...
The AMBULATE pivotal study met its primary efficacy endpoint. The median time to patients getting on their feet following arrhythmia ablation procedures was reduced by 3.9 hours. AMBULATE demonstrated that patients in the VASCADE MVP arm had significantly improved patient satisfaction and a significant ...
BioTrace Medical’s innovative Tempo Temporary Pacing Lead is designed for secure and stable pacing with the goal of reducing complications and allowing patients to ambulate sooner after procedures such as TAVR. The Tempo Lead’s unique design – featuring a novel retractable fixation mechanism and a soft tip – reduces the risks of ...
In addition, results of a single-center retrospective study of 112 patients demonstrating the safety and efficacy of the Tempo Lead will be presented by Daniel S. ...
In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as TAVR and TMVR, accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU. ...
The physician-sponsored analysis further demonstrates that the Tempo Lead’s unique design facilitates safe ambulation during post-procedure temporary pacing. Tempo Lead post-procedure use (n=159, 71 percent) had a mean time of 42 hours (range of 2.5 hours to 9 days) with final post-procedural PCT of 0.8±1.0mA (n=81). One hundred thirty-seven patients ...
The symposium will feature recent clinical experience and case studies from several leading U.S. transcatheter valve aortic replacement (TAVR) centers, highlighting the safety and efficacy of the Tempo Lead, and its positive impact on facilitating post-TAVR patient ambulation and reducing length of stay. These results were observed in more than 500 cases with no ...
Device success was achieved in 9 patients (90%). The device was not deployed in one patient due to operator failure to follow the IFU. Time to cessation of bleeding overall was 3.1 ± 3.1 min. and was 2.4 ± 2.4 min. in patients with device success. There was no change in the quality of pedal pulses in any patient ...